Cargando…
IAP inhibitor plus chemoradiotherapy for the treatment of bulky anal canal carcinoma
The aim of this editorial is to focus on the urgent need to improve clinical outcomes in patients with bulky primary anal canal carcinoma.
Autores principales: | De Felice, Francesca, Franco, Pierfrancesco |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10645633/ https://www.ncbi.nlm.nih.gov/pubmed/37962690 http://dx.doi.org/10.1007/s12032-023-02224-1 |
Ejemplares similares
-
Sarcopenia Is Associated With Hematologic Toxicity During Chemoradiotherapy in Patients With Anal Carcinoma
por: Martin, Daniel, et al.
Publicado: (2020) -
Chemoradiotherapy in squamous cell carcinoma of the anal canal: a single institution experience
por: Kim, Kyung Hwan, et al.
Publicado: (2013) -
Scoping Renal Cell Carcinoma in the Rectal and Anal Canal: A Literature Review
por: Anwar, Shamsuddin M, et al.
Publicado: (2019) -
C-Reactive Protein-to-Albumin Ratio as Prognostic Marker for Anal Squamous Cell Carcinoma Treated With Chemoradiotherapy
por: Martin, Daniel, et al.
Publicado: (2019) -
High-grade neuroendocrine small-cell carcinoma of the anal canal: Long-term remission with chemoradiotherapy
por: Hajjar, Roy, et al.
Publicado: (2021)